Latest news with #DeanLi
Korea Herald
27-06-2025
- Business
- Korea Herald
CKGSB Dean Li Haitao Illuminates on China's AI Trajectory at 2025 Summer Davos
TIANJIN, China, June 27, 2025 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB) Dean and Dean's Distinguished Chair Professor of Finance Li Haitao spoke at the Annual Meeting of the New Champions 2025 of the World Economic Forum, widely known as Summer Davos, in Tianjin, China, for the second year in a row, a testament to the school's thought leadership and acknowledgement. This year's Summer Davos focused on entrepreneurship for a new era. As the most active Chinese business school this year at the Summer Davos, CKGSB contributed to the discourse on multiple meaningful topics including AI reshaping global competition and entrepreneurship in the new era. In the session broadcast live globally on June 26, "Understanding China's approach to AI," Dean Li joined leading voices to explore China's advantage in developing AI amid re-globalization, industrial possibilities brought by AI, and how AI can propel doing business for good by providing scarce resources. "Only two countries, China and the US, can lead AI revolution in the next decades," emphasized Dean Li. "China has done lots of accumulation for decades with infrastructure, data, talent, and market to establish a unique AI ecosystem. Beyond home appliances, smartphones, and automobiles, humanoid robots have the greatest potential to become a trillion-dollar industry in China. CKGSB aspires to systematically prepare business leaders for what the AI era requires for strategic architecture capabilities and new leadership skills." Moderated by renowned journalist Yang Lan, the panel also featured executives and scholars including Unitree Robotics Founder and CEO Wang Xingxing, Haier CEO Zhou Yunjie, USC Professor of Law Angela Zhang Huyue, and Workera Founder and CEO Kian Katanforoosh. In addition, Dean Li delivered a keynote speech at the session around Gen Z consumers. He noted that with Gen Z's robust purchasing power and authentic passion for eco-conscious consumption, and as more start to evaluate companies' sustainable commitment when making career decisions, companies must build a new collaboration structure where people at all levels get to affect decision making, contribute their own knowledge and jointly create value. Dean Li also participated at the Global University Leaders Meeting, discussing how higher education institutions should shape the future of research through partnerships and continue to serve as engines of innovation. CKGSB also co-hosted CKGSB's 2025 Davos Night in collaboration with Tencent's Tencent News.
CNBC
09-06-2025
- Health
- CNBC
FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
The Food and Drug Administration on Monday approved Merck's shot designed to protect infants from respiratory syncytial virus during their first season of the virus, bringing to market a rival to a similar treatment from Sanofi and AstraZeneca. The decision will allow the company to launch the drug, which will be marketed as Enflonsia, ahead of the RSV season that typically kicks off around fall and winter and lasts through the spring. Merck said in a release that it expects orders for the shot to begin in July, with shipments delivered before the virus starts to spread widely. The approval gives doctors a new treatment option for the virus, which causes thousands of deaths among older Americans and hundreds of deaths among infants each year. Complications from RSV are the leading cause of hospitalization among newborns. "We are committed to ensuring availability of [Enflonsia] in the U.S. before the start of the upcoming RSV season to help reduce the significant burden of this widespread seasonal infection on families and health care systems," Dr. Dean Li, president of Merck Research Laboratories, said in a release. Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented demand. Both are preventative monoclonal antibodies, which deliver antibodies directly into the bloodstream to provide immediate protection. But each targets a different part of the virus, making it difficult to compare them directly. Merck's treatment can be administered to infants regardless of their weight, which the company said may offer convenience in terms of dosing. Meanwhile, the recommended dosage of Beyfortus is based on an infant's body weight. Sanofi on Monday revealed an aggressive effort to increase supply of Beyfortus, including a plan to begin shipping the shot early in the third quarter. Last year, Beyfortus booked sales of €1.7 billion ($1.8 billion). Vaccines for RSV are also available in the U.S. from companies such as Pfizer, GSK and Moderna. But those shots are only for use in adults or in pregnant women. Recently, the FDA paused testing of RSV shots in young children while it evaluates safety concerns. All of the companies in the market are waiting for a meeting of outside vaccine advisors to the Centers for Disease Control and Prevention from June 25 to 27, when they will form recommendations for RSV shots and other immunizations. In the mid- to late-stage trial on Enflonsia, the treatment reduced RSV-related hospitalizations by more than 84% and decreased hospitalizations due to lower respiratory infections by 90% compared with a placebo among infants through five months. The shot also reduced lower respiratory infections that required medical attention by more than 60% compared with a placebo through five months. RSV is a common cause of lower respiratory tract infections such as pneumonia.
Yahoo
09-06-2025
- Business
- Yahoo
Merck claims study success with PCSK9 cholesterol pill
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. An experimental cholesterol-lowering pill from Merck & Co. succeeded in a pair of late-stage studies, the company said Monday. In one study, Merck's drug, enlicitide, was tested against a placebo in people already taking statins and who have either an inherited condition that causes high cholesterol or are at risk of atherosclerosis. The second trial evaluated enlicitide against other oral therapies, such as ezetimibe, in people on statins and with abnormally high levels of fats in the blood. Merck didn't provide specifics, but said in both cases enlicitide met all of its study objectives and demonstrated 'statistically significant and clinically meaningful reductions' in LDL-C, or 'bad' cholesterol, without any important differences in the number of adverse events. Details will be presented at a future medical meeting. Company shares climbed 2% in early trading Monday. A decade ago, the Food and Drug Administration approved a pair of injectable treatments that could dramatically lower cholesterol in people with heart disease. The drugs, known as PCSK9 inhibitors for the cholesterol-regulating protein they target, were hailed as medical breakthroughs and billed as multibillion-dollar sellers. Instead, their developers struggled to convince payers and physicians of their worth. Sales totals, until recently, have largely disappointed. Merck believes it will have better luck with enlicitide, which could be the first oral medication that blocks PCSK9. The company has bet heavily on its future, enrolling about 17,000 participants across several late-stage studies. And it's counting on enlicitide to become one of the products that can help it grow sales once the patents protecting Keytruda, its dominant cancer immunotherapy, expire later this decade. Questions about its post-Keytruda future have spurred a 40% share slide over the last year and heightened pressure on its next prospects to succeed. The company, for its part, has spoken boldly about enlicitide's promise. Research chief Dean Li has described it as likely becoming the first of its kind available, the 'most effective' cholesterol-lowering pill medicine on the market, and the foundation for future drug combinations. Enlicitide should also be able to sidestep the reimbursement issues long weighing down sales of PCSK9 blockers, CEO Robert Davis said during a presentation in January. Though the drug is a so-called macrocyclic peptide and thus more complicated to make than traditional small molecule pills, Merck has invested significantly in production and believes it can manufacture enlicitide at a low cost. That could help the company 'price it in a way that won't create the excess challenges' others have had and obtain a 'competitive advantage,' Davis said. Still, there is a large collection of branded and generic cholesterol drugs available, as well as multiple newer medicines in advanced testing. AstraZeneca, for one, has a PCSK9 pill in development that some analysts believe to be a meaningful threat to Merck's program. While there are 'early signs' Merck's drug might be more effective, AstraZeneca's could be 'more tolerable and easier to administer,' Leerink Partners analyst Daina Graybosch wrote in April. The size of enlicitide's effects in Phase 3 testing, then, will be closely scrutinized. In Phase 2 trials, a variety of enlicitide doses lowered LDL levels by up to 60% after eight weeks of treatment. One of the Phase 3 studies Merck reported on Monday tested cholesterol levels after 24 weeks, and there is typically a 'degradation in efficacy' when companies move a drug into larger, longer trials, wrote Jefferies analyst Dennis Ding. Ding also speculated that drug adherence could be lower in Merck's studies, as food intake disrupts enlicitide effectiveness. 'The magnitude of benefit will be key to watch,' he wrote.
